Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

501
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
501
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

5.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Structure and Function of Platelets01:18

Structure and Function of Platelets

1.1K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.1K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

2.6K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study on the influence mechanism of environmental perception on physical health status-with lifestyle as the mediating variable.

Frontiers in public health·2026
Same author

TET3 facilitates bladder cancer progression through targeted modulation of stemness pathways.

Medical oncology (Northwood, London, England)·2025
Same author

Platelet Disorders and Medication Strategies.

Thrombosis and haemostasis·2025
Same author

Design, synthesis and FXR partial agonistic activity of anthranilic acid derivatives bearing aryloxy moiety as therapeutic agents for metabolic dysfunction-associated steatohepatitis.

Bioorganic chemistry·2024
Same author

Role of Platelets and Their Interaction with Immune Cells in Venous Thromboembolism.

Seminars in thrombosis and hemostasis·2024
Same author

Mechanism of Bile Acid in Regulating Platelet Function and Thrombotic Diseases.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2024

Related Experiment Video

Updated: Jun 16, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.6K

HMGB1-Platelet Interactions: Mechanisms and Targeted Therapy Strategies.

Xiyuan Fang1,2,3, Xianghui Zhou1, Xin Zhou4,5

  • 1Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, People's Republic of China.

Thrombosis and Haemostasis
|June 13, 2025
PubMed
Summary

High mobility group box 1 (HMGB1) released by platelets drives inflammation and thrombosis. Targeting the HMGB1-platelet axis offers new therapeutic strategies for inflammatory thrombotic disorders.

More Related Videos

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

7.6K
Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice
11:18

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Published on: April 2, 2013

15.7K

Related Experiment Videos

Last Updated: Jun 16, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.6K
A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

7.6K
Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice
11:18

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Published on: April 2, 2013

15.7K

Area of Science:

  • Immunology
  • Hematology
  • Molecular Biology

Background:

  • Platelets are key regulators of inflammation and hemostasis.
  • High mobility group box 1 (HMGB1) is an inflammatory mediator released by platelets.
  • HMGB1 signaling reciprocally activates platelets via Toll-like receptors (TLRs) and RAGE.

Purpose of the Study:

  • To systematically characterize the HMGB1-platelet axis.
  • To elucidate the context-dependent roles of HMGB1-platelet interactions in disease.
  • To evaluate therapeutic strategies targeting HMGB1 and platelet activity.

Main Methods:

  • Literature review of HMGB1-platelet axis.
  • Analysis of HMGB1 signaling pathways in platelet activation.
  • Evaluation of therapeutic interventions for HMGB1 and platelet modulation.

Main Results:

  • Platelet-derived HMGB1 mediates bidirectional communication with immune cells.
  • HMGB1-induced platelet activation promotes inflammation-associated thrombosis.
  • The HMGB1-platelet axis plays significant roles in various pathological conditions.

Conclusions:

  • The HMGB1-platelet axis is a critical driver of inflammation and thrombosis.
  • Targeting this axis presents therapeutic potential for thrombotic disorders.
  • Future research should focus on dual-target interventions for enhanced efficacy.